Oramed Pharmaceuticals
ORMP
57 hedge funds and large institutions have $37.2M invested in Oramed Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
53% more capital invested
Capital invested by funds: $24.3M → $37.2M (+$12.9M)
21% more funds holding
Funds holding: 47 → 57 (+10)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
10.34% more ownership
Funds ownership: 22.46% → 32.81% (+10%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$668K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$217K |
| 3 |
HF
HRT Financial
New York
|
+$119K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$108K |
| 5 |
Squarepoint
New York
|
+$73.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$1.06M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$602K |
| 3 |
BlackRock
New York
|
-$50.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$19.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ME
51
McIlrath & Eck
Arlington,
Washington
| $2.85K | – | – | – |
|
|
CJ
52
Caitlin John
Brighton,
Michigan
| $2.85K | +$2.58K | +1,000 | New |
|
53
Jones Financial Companies
Des Peres,
Missouri
| $2.04K | – | – | – |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| $1.98K | +$1.79K | +693 | New |
|
55
Fidelity Investments
Boston,
Massachusetts
| $1.43K | – | – | – |
|
|
IA
56
IFP Advisors
Tampa,
Florida
| $1.43K | – | – | – |
|
|
GSWM
57
Golden State Wealth Management
Santa Ana,
California
| $864 | – | – | – |
|
58
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9K | -3,483 | Closed |
|
|
NFSG
59
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$2.64K | -1,000 | Closed |
|
|
AF
60
Allworth Financial
Folsom,
California
| – | -$792 | -300 | Closed |
|
|
HFS
61
Hopwood Financial Services
Reston,
Virginia
| – | -$528 | -200 | Closed |
|
62
Citigroup
New York
| – | -$11 | -4 | Closed |
|
ORMP Hedge Fund Activity: Q4 2025 in Review
57 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2025, worth a combined $37.2M — up 53% from $24.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ORMP positions and 5 closed out — a net gain of 10 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $668K. The largest seller was Murchinson, cutting an estimated $1.06M.
- 57 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2025, up from 47 in Q3 2025.
- Funds reported $37.2M of Oramed Pharmaceuticals stock for Q4 2025, up 53% quarter-over-quarter.
- 15 funds opened new Oramed Pharmaceuticals positions in Q4 2025 and 5 closed out, a net change of +10 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2025 was Marshall Wace, an estimated $668K added.
- The largest Oramed Pharmaceuticals seller in Q4 2025 was Murchinson, an estimated $1.06M sold.
Based on aggregated 13F filings for Q4 2025.